UK Markets open in 1 hr 20 mins

Acurx Pharmaceuticals, Inc. (ACXP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
4.4000-0.0350 (-0.79%)
At close: 04:00PM EST
Sign in to post a message.
  • m
    morgan
    Summit didn’t meet their phase 3 endpoint. Summit was ACXP’s primary competition. Let the buss begin!
  • m
    morgan
    $20+ in 8 months or less
    $50+ in 18 months

    Total hidden gem
  • m
    morgan
    Just a total gem that has potential to 5-6x in less than 6 months. $Summit failed phase 3 and is still at $200mm market cap. Meanwhile, this drug has had a perfect track record with leading scientists from summit now on $acxp scientific advisory board. $43mm market cap is wildly low. Founder owned and founder led: this thing is going to buss
  • m
    morgan
    -100% cure. 0% recurrence. Way better than vanco. Way better than summit.
    -30% insider ownership
    -continual insider buying
    -500M sales at only 20% market penetration
    -most compelling pick according to biopub
    -pasteur act potential
    -best medical advisor board
    -restores microbiome unlike any other option
    -amr fund potential
    - Novo nordisk fund potential
    -icing in the cake is 1B sales on their clinical stage acx-375 if approved and achieves only 4% penetration

    If they are front line drug for cdiff and have a ps ratio of 4 that implies a market cap of 6B. Which would be a 125x upside

    125x plus whatever they get from axc-375
  • m
    morgan
    This about to take off. 7.5mm float with crazy solid fundamentals. Summit went to $500mm on 2B and is looking to get non-inferior designation. at best against vanco. ACXP’s ibezapolstat has had 100% perfect results thus far and is sitting at a low low $40mm market cap. Get ready for the buss train to leave the station!
  • m
    morgan
    Going to buss so very soon. They may get bought out even before 2B. I hope not, cause sky is the limit for this if this takes vanco’s spot as leading drug for c-diff
  • m
    morgan
    This stock is drastically undervalued. Summit is still over $250mm and they have a failed primary drug and a preclinical drug. ACXP is the front runner now with perfect data thus far, as well as has a preclinical drug and has $44mm market cap! How does this make sense?! Summit went to $500mm market cap on 2B. Expect a massive explosion upwards to $15-$20 on 2B data which is due may-June timeframe
  • g
    gabe
    With a Buy rating, Maxim Group initiated coverage on Acurx Pharmaceuticals Inc (NASDAQ:ACXP). The price target seems to have been set at $12.00 for Acurx Pharmaceuticals. For the third quarter, Acurx Pharmaceuticals had an EPS of $0.46, compared to year-ago quarter EPS of $0.21. At the moment, the stock has a 52-week-high of $8.74 and a 52-week-low of $3.71. Acurx Pharmaceuticals closed at $4.89 at the end of the last trading period.
  • s
    simon
    No news is good news
  • D
    Dave
    Someday
  • W
    WilliamJ
    Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference

    See Yahoo headline
  • g
    gabe
    Boom
  • D
    Donny
    I just bought 1.5k should i worry?
  • S
    Senga
    And to Jupiter after phase 3, If it's positive outgoing.👍
  • M
    Marc
    Incredible P2A data - patients have been 100% cured with no recurrence of CDI. P2b data should confirm and launch this thing to the moon. I got in pre-IPO and really like the odds here.
  • a
    adam
    Stock will be over $25 on good phase 2B data.
  • D
    Dave
    I'm in. Sounds like a winner.
  • D
    Dragan
    Appears good price entry IPO
  • D
    Dragan
    Here we go. Antibiotics are "easy" FDA approval. New class, targeting resistant bacteria.